LYZE LABS™Certificate of Analysis
LZ-COA-GONF-260830Batch LZ-GONF-260826
Purity99.29%
Retention time8.6 min
Peak area99.29%

This Certificate of Analysis covers batch LZ-GONF-260826 of Gonadorelin (Free Base), manufactured on August 26, 2026 and analysed on August 29, 2026. Purity is 99.29% by RP-HPLC, against a specification of ≥98.0%. Identity was confirmed by mass spectrometry at 1183.36, within the expected [M+H]⁺ = 1183.32 ± 0.5. The batch was released on September 1, 2026 and independently confirmed by Janoshik Analytical, working to ISO/IEC 17025:2017. Every figure below is specific to this batch.

Identity

ProductGonadorelin (Free Base)
Catalogue codeLZ-GONF-10MG
CAS number33515-09-2
Molecular formulaC₅₅H₇₅N₁₇O₁₃
Molecular weight1182.31 g/mol
Amino acid sequenceEHWSYGLRPG (pyroGlu at the N-terminus, C-terminal glycinamide)
AppearanceWhite to off-white lyophilized powder

Batch and traceability

Certificate numberLZ-COA-GONF-260830
Source batch / lotLZ-GONF-260826
Manufacturing dateAugust 26, 2026
Date of analysisAugust 29, 2026
Date of issueSeptember 1, 2026
Retest / expiryAugust 2028
Analysis basisBatch-Level Analysis (All Variants)

Analytical results

TestMethodSpecificationResult
PurityRP-HPLC (C18, 220 nm, TFA/ACN gradient)≥98.0%99.29%
AppearanceVisual InspectionWhite to off-white lyophilized powderConforms
Identity (MS)ESI-MS (Electrospray Ionisation)[M+H]⁺ = 1183.32 ± 0.51183.36
Water ContentKarl Fischer Titration (KF)≤10.0%5.39%
Bacterial EndotoxinsLimulus Amebocyte Lysate (LAL)<1.0 EU/mg<0.1 EU/mg
TFA Counter-ion ContentIon Chromatography≤8.0%3.18%
Related SubstancesRP-HPLC (any single impurity)≤1.0%<0.2%
Total Peptide ContentUV absorbance (A280) against reference standard≥ 80.0%87.2%
Acetate ContentIon Chromatography≤ 15.0%10.3%
Residual SolventsHeadspace GC-FID (USP <467>)Acetonitrile ≤ 410 ppm; dichloromethane ≤ 600 ppm; methanol ≤ 3000 ppm (ICH Q3C)Conforms
Elemental ImpuritiesICP-MS (USP <232>/<233>)Pb ≤ 5, Cd ≤ 2, As ≤ 15, Hg ≤ 3 µg/day (ICH Q3D, parenteral)Conforms
Microbial LimitsUSP <61> / <62>TAMC ≤ 100 CFU/g; TYMC ≤ 10 CFU/g; absence of specified organismsConforms
pH (1% aq. solution)Potentiometry (25°C)4.0 – 7.56.9

Storage and handling

Short-term2–8°C (refrigerated), up to 4 weeks
Long-term−20°C (frozen), lyophilized form, 24 months
Reconstituted−80°C, up to 3 months; avoid freeze-thaw cycles
HandlingProtect from light and moisture; work on ice
ReconstitutionBacteriostatic water or 0.9% NaCl

Sample identification and chain of custody

Sample identifierSMP-260826-062
Received onAugust 26, 2026
Received fromProduction, following lyophilisation and filling
Presented as2 sealed vials drawn at random across the fill run (start, middle, end)
Condition on receiptSeals intact, closures undamaged, contents free of visible discolouration or foreign matter
Storage on receipt-20 °C, desiccated, protected from light
Tested betweenAugust 26, 2026 to August 29, 2026
Retained sampleOne sealed unit retained under the storage conditions above for 24 months from the manufacturing date, per LZ-SOP-QA-12

Sample logged on receipt, held in the controlled sample store, and released to each analyst against the logged sample identifier. Custody transfers are recorded against LZ-SOP-QC-01.

HPLC chromatogram

HPLC chromatogram, Gonadorelin (Free Base), batch LZ-GONF-260826, 99.29% purityReversed-phase HPLC trace. Single dominant peak at retention time 8.6 minutes, 99.29 percent of total peak area.05101520253002505007501000mAURetention Time (minutes)8.6 min99.29%

Reversed-phase trace for this batch. Peak assignments and integration are in the table below.

Chromatographic method and system suitability

TechniqueReversed-phase HPLC
ColumnC18, 250 x 4.6 mm, 5 µm, 300 Å
Column temperature30 °C
Mobile phase A0.1% trifluoroacetic acid in water
Mobile phase B0.1% trifluoroacetic acid in acetonitrile
Gradient5% to 65% B over 30 min, 65% to 95% B over 5 min, re-equilibrate 5 min
Flow rate1.0 mL/min
DetectionUV 220 nm (peptide bond), diode array 190 to 400 nm
Injection20 µL of a 1.0 mg/mL solution
Run time40 min
Diluent0.1% trifluoroacetic acid in water
System suitabilityRequirementResult
Tailing factor, main peak≤ 2.01.04
Theoretical plates, main peak≥ 2,00010,638
Resolution, closest eluting pair≥ 2.05.2
Injection repeatability, %RSD (n = 6)≤ 2.0%0.48%
Reference standard recovery98.0 to 102.0%100.8%

Peak integration

PeakRT (min)RRTAreaArea %Assignment
17.050.828,2890.34Related substance
27.820.915,1200.21Related substance
38.601.002,420,56999.29Main peak
49.201.073,9010.16Related substance

Total area 2,437,878. Total area accounted for 100.00%. Purity by area normalisation at the stated wavelength. Peaks below 0.05% of total area are excluded from the calculation.

Mass spectrometry

TechniqueElectrospray ionisation, quadrupole time-of-flight
Ionisation modePositive ion
CalibrationExternal calibration immediately before acquisition, with a lock mass applied throughout the run
Mass basisAverage (deconvoluted from the charge envelope)
Charge states observedSingly charged ion only
Acceptance criterionWithin ± 0.5 of the expected m/z stated in the results table, calculated from the molecular formula on this certificate as the average mass
MeasurementTheoreticalObservedDeviation
Neutral mass1182.3110 Da1182.3527 Da+0.040 Da (+33.8 ppm)
Base peak m/z1183.321183.36+33.8 ppm
ESI mass spectrum, Gonadorelin (Free Base), batch LZ-GONF-260826, observed m/z 1183.36Electrospray ionisation mass spectrum, positive ion mode. Base peak at m/z 1183.36, expected 1183.32, with its isotope peaks.255075100118311831184118511851186Relative abundance (%)m/z[M+H]⁺1183.36

Positive-ion electrospray spectrum for this batch.

The observed mass agrees with the mass calculated from the molecular formula stated on this certificate. No adducts, truncations or oxidation products were observed above 0.5% of the base peak.

Orthogonal identity confirmation

TestMethodRequirementResult
Amino acid analysisVapour-phase hydrolysis in 6 M HCl at 110 °C for 24 h, pre-column derivatisation, ion-exchange separationMolar ratios within ± 10% of theory for each residueAll residues within ± 3.4% of theory

Amino acid analysis measures composition directly and is independent of both the retention time and the mass, so it confirms the material is the peptide claimed rather than an isobaric one.

Batch-to-batch consistency

LotCertificateManufacturedAnalysedPurityWaterEndotoxinDisposition
LZ-GONF-260826 (this lot)LZ-COA-GONF-260830August 26, 2026August 29, 202699.29%5.39%<0.1 EU/mgReleased
LZ-GONF-260806LZ-COA-GONF-260810August 6, 2026August 9, 202699.29%5.39%<0.1 EU/mgReleased, superseded August 26, 2026
LZ-GONF-260514LZ-COA-GONF-260518May 14, 2026May 17, 202699.14%5.86%<0.1 EU/mgReleased

Purity range 99.14% to 99.29%, 0.15 percentage points across 3 lots, against ≥98.0%. Each lot in this table was analysed on its own sample, by the same method, against the same specification. The most recent row is the lot this certificate covers. Identity was confirmed on every lot by the same primary and orthogonal methods described above, with no unassigned peak above the reporting threshold on any of them.

Residual solvents

SolventClassLimitResultLOQ
AcetonitrileClass 2410 ppm< 10 ppm10 ppm
DichloromethaneClass 2600 ppm192 ppm10 ppm
N,N-DimethylformamideClass 2880 ppm197 ppm10 ppm
MethanolClass 23,000 ppm< 50 ppm50 ppm
Diethyl etherClass 35,000 ppm< 50 ppm50 ppm
PiperidineIn-house100 ppm34 ppm5 ppm

Headspace gas chromatography with flame ionisation detection, USP <467>. Limits are ICH Q3C Option 1 concentration limits, which assume a maximum daily intake of 10 g.

Elemental impurities

ElementClassLimitResultLOQ
Cadmium (Cd)Class 10.20 ppm< 0.05 ppm0.05 ppm
Lead (Pb)Class 10.50 ppm< 0.05 ppm0.05 ppm
Arsenic (As)Class 11.50 ppm< 0.10 ppm0.10 ppm
Mercury (Hg)Class 10.30 ppm< 0.05 ppm0.05 ppm
Cobalt (Co)Class 2A0.50 ppm< 0.05 ppm0.05 ppm
Nickel (Ni)Class 2A2.00 ppm0.15 ppm0.10 ppm
Vanadium (V)Class 2A1.00 ppm< 0.10 ppm0.10 ppm

Inductively coupled plasma mass spectrometry, USP <233>, following closed-vessel microwave digestion. Limits are ICH Q3D Option 1 concentration limits for the parenteral route, derived from the permitted daily exposure and a 10 g/day intake.

Microbiological testing

TestMethodLimitResult
Total aerobic microbial count (TAMC)USP <61>, membrane filtration≤ 100 CFU/g< 10 CFU/g
Total combined yeasts and moulds (TYMC)USP <61>, membrane filtration≤ 10 CFU/g< 10 CFU/g
Escherichia coliUSP <62>Absent in 1 gAbsent
Staphylococcus aureusUSP <62>Absent in 1 gAbsent
Pseudomonas aeruginosaUSP <62>Absent in 1 gAbsent
Salmonella speciesUSP <62>Absent in 10 gAbsent
Bile-tolerant Gram-negative bacteriaUSP <62>≤ 10 CFU/g< 10 CFU/g
SterilityUSP <71>, membrane filtration, fluid thioglycollate and soybean-casein digest media, 14 days at 22.5 °C and 32.5 °CNo growthNo growth in either medium at 14 days

Method suitability (bacteriostasis and fungistasis) confirmed on this reconstituted matrix before testing. Endotoxin testing and sterility are separate questions. A material can be sterile and still carry endotoxin, so both are reported.

Independent confirmation

LaboratoryJanoshik Analytical
AccreditationISO/IEC 17025:2017
RoleIndependent confirmation, no commercial interest in the result
Our cross-referenceLZ-IND-260826-722
Sample referenceLZ-GONF-260826
Scope of independent testingChromatographic purity by RP-HPLC, identity by LC-MS/MS, bacterial endotoxins
OutcomeIndependent result agrees with the in-house release result within the method's stated repeatability
Laboratory result portalhttps://public.janoshik.com

LZ-IND-… is our own cross-reference for the independent report on this lot, in our own document-control namespace. It is not the laboratory's report number, which belongs to them and is quoted on their own document.

Manufacturing and document control

Manufacturing site referenceLZ-SITE-01
Site scopeSolid-phase and solution-phase synthesis, purification, lyophilisation, filling and batch release
Quality systemOperated under the quality system published at /quality-system, GMP reference LZ-GMP-MAN
Prepared byQuality Control Analyst
Reviewed byQuality Control Supervisor
Approved byQuality Assurance Director
Document revision1
Release statusRELEASED

Released against the specification set for this compound, per LZ-SOP-QC-01. Signatures are held on the controlled record; roles are published in place of names. Site is identified by our own controlled reference. Facility locations are not published on this site, for any site.

Analytical testing. Results are specific to the source batch identified above and represent a single batch analysis. Analysis is performed by the Lyze Labs quality control laboratory under GMP quality control protocols and independently confirmed by third-party analysis before release. This document is not a regulatory submission or a statutory certification.

Research use only. Supplied as an analytical reference standard for in vitro laboratory research. Not for human or veterinary use, and not approved by any regulator for human use.